MDCO
The Medicines Company
Healthcare
03/02/2015
Presented
| Date | 02/27/2015 |
| Price | $28.77 |
| Market Cap | $1.87B |
| Ent Value | $1.76B |
| P/E Ratio | N/A |
| Book Value | $14.12 |
| Div Yield | N/A |
| Shares O/S | 65.01M |
| Ave Daily Vol | 2,440,000 |
| Short Int | 14.50% |
Current
| Price | $84.90 |
| Market Cap | $6.77B |
| The Medicines Company provides medical solutions for patients in acute and intensive care hospitals worldwide. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for use in patients undergoing percutaneous coronary intervention; Recothrom, a human recombinant thrombin used as an aid to hemostasis; Cleviprex, an intravenous small molecule calcium channel blocker for blood pressure reduction; Minocin IV, an antibiotic for the treatment of infections due to gram-negative bacteria, including Acinetobacter species; and ready-to-use formulation of Argatroban for the treatment of thrombosis. Its products under development include Cangrelor, an intravenous small molecule antiplatelet agent for the prevention of platelet activation and aggregation; Oritavancin, an investigational intravenous antibiotic for the treatment of acute bacterial skin related infections; and IONSYS, a pre-registration stage product for the short-term management of acute postoperative pain. The company’s products under development also comprise Fibrocaps, which is used as an aid to stop bleeding during surgery; RPX-602 for the treatment of infections; MDCO-216, a novel biologic product to reverse atherosclerotic plaque development and reduce the risk of coronary events in patients with ACS; Carbavance, an antibiotic agent for the treatment of hospitalized patients with bacterial infections; and ALN-PCSsc, a subcutaneously administered RNA interference therapeutic for the treatment of hypercholesterolemia. In addition, it offers acute care generic products for use in the cardiovascular and neurocritical care; and promotes BRILINTA, an oral tablet antiplatelet medicine. The company has collaborations with Alnylam Pharmaceuticals, Inc. and AstraZeneca LP. The Medicines Company was founded in 1996 and is based in Parsippany, New Jersey. |
Publicly traded companies mentioned herein: Hospira Inc (HSP), The Medicines Company (MDCO)
Highlights
Despite near term patent/ generic risk, the presenter is long shares of The Medicines Company (MDCO), and sees the specialty pharma company “traversing into biotech.” He believes there is substantial value in a diverse pipeline that is not priced into the stock at present levels (~$28), and in the long run (2 years out) there is optionality around a potential takeout.
◆Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.
◆Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.